Dr. Martin Pfister

Principal / Authorized Signatory

Dr. Martin Pfister

Principal / Authorized Signatory

Dr. Martin Pfister studied medicine and pharmacy at the University of Greifswald and New York University and received his doctorate in immunology. He worked in various academic laboratories. Since 2000 he has been active in the start-up scene. He took over management positions and is co-founder of two successful companies in the fields of diagnostics & health services. In 2010 he transferred to the HTGF on the investor side. With his long-standing experience in drug development/gene therapy and medical technology/diagnostics, he is a valued sparring partner for portfolio companies in the fields of biotechnology and healthcare. He also holds several advisory board positions with portfolio companies.

Contact

Telefon:
+49 – (0)228 – 82300 – 123

Portfolio

Posts & mentions

Blog
Blog
5. October 2021

Life Science Pitch Day: Real entrepreneurs, real innovation, real added value

It was a special moment when CureVac founder Ingmar Hoerr shared his business story at the Life Science Pitch Day. More than 30 start-ups, investors, and scientists took part in the event at the end of September, which was organised by High-Tech Gründerfonds (HTGF) together with partners Bayer, Boehringer Ingelheim and the Innovation and Start-Up Center Biotechnology (IZB). We spoke to the event organisers at HTGF: Dr. Caroline Fichtner and Dr. Martin Pfister, both HTGF Principals, touched
 
Press
25. August 2021

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a €64 million ($76 million) Series B financing round. The round was led by Inkef Capital, supported by fello
 
Press
2. August 2021

Successful exit for High-Tech Gründerfonds – HTGF fund investor Evonik acquires biotech company JeNaCell

Acquisition of JeNaCell expands Evonik’s portfolio of biomaterials used in medical technologyJeNaCell to realize full potential of its innovative technology and further expand its technology portfolio with Evonik’s supportHigh-Tech Gründerfonds (HTGF) financed the seed round in 2012 together with the Foundation for Technology, Innovation and Research Thuringia (STIFT)bm|t acquired stake in JeNaCell in 2015 together with Sparkasse Jena-Saale-Holzland and HTGF fund investor Evonik Venture
 
Press
26. January 2021

GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases

Proceeds will facilitate development of GeneQuine’s gene therapy pipeline for musculoskeletal disorders and vector platformLead gene therapy candidate GQ-303, a potentially disease-modifying treatment for osteoarthritis, will be advanced to Phase 1 clinical trialGene therapy program for intervertebral disc degeneration will be acceleratedCompany is expanding with additional site and staff GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for mu
 
Press
17. November 2020

lino Biotech closes seed financing round and showcases a novel label-free biosensor platform for innovate modern drug screening

After almost a decade of initial invention and joint research on the Focal Molography technology at Roche, a leading player in the diagnostics and pharmaceutical area, and ETH Zurich as one of Europe’s most renowned research institutes, lino Biotech AG has licensed the technology to further develop and commercialize Focal Molography. The company has received 7-digit financing from lead-investors HTGF, Roche Ventures and several family offices. This broadly patented technology offers lab
 

Events

Event
6. October 2022
7th Life Science Pitch Day
In cooperation with Bayer, Boehringer Ingelheim and MEDICE, High-Tech Gründerfonds and the IZB are organizing the 7th LIFE SCIENCE PITCH DAY! Take your opportunity and present your technology in front of an exclusive audience of investors and CVCs! The Life Science Pitch Day is finally back. Once again, we would like to welcome you to our yearly event which will take place on the 6th October, 2022 in Munich.You will get the opportunity to listen to interesting keynotes from relevant industry p